TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17509313

Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate (42 mEq potassium, 21 mEq magnesium, 63 mEq citrate per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15741846

Group type: COMPARATOR
Intervention: Control trial (accurate feedback at each kilometer split)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increase trial (inaccurate feedback starting at 0.775 km, increasing by 25 m each split)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Decrease trial (inaccurate feedback starting at 1.25 km, decreasing by 25 m each split)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Random trial (randomized distance splits)
Number of subjects: 15
Study: 11839621

Group type: EXPERIMENTAL
Intervention: Conservative, ischemia-guided strategy
Number of subjects: 876

Group type: COMPARATOR
Intervention: Routine invasive strategy
Number of subjects: 876
Study: 10081528

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g given rectally
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 7567210

Group type: EXPERIMENTAL
Intervention: Cold air hyperventilation (CAH)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (MCH)
Number of subjects: 17
Study: 2210246

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 6778324

Group type: EXPERIMENTAL
Intervention: Penicillin V (55 mg/kg/day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: COMPARATOR
Intervention: Penicillin V (55 mg/kg/day) and Placebo
Number of subjects: 149
Study: 30535345

Group type: EXPERIMENTAL
Intervention: Targeted electronic health record (EHR) alert
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Control (no EHR alert)
Number of subjects: 1021
Study: 28790113

Group type: EXPERIMENTAL
Intervention: SR48692 (NTSR1 antagonist) combined with carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 0
Study: 25801542

Group type: EXPERIMENTAL
Intervention: 150 mg intravenous fosaprepitant (NKI group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 4 mg ondansetron (ONS group)
Number of subjects: 44
Study: 22578715

Group type: EXPERIMENTAL
Intervention: Psychological flexibility (assessed by AAQ‐II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mindfulness (assessed by KIMS)
Number of subjects: 30
Study: 21824612

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Regular colonoscopy (RC)
Number of subjects: 329
Study: 19302271

Group type: EXPERIMENTAL
Intervention: Cue location validity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background luminance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Location vs. color
Number of subjects: 0
Study: 17410046

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 134
Study: 12464713

Group type: EXPERIMENTAL
Intervention: Paroxetine up to 20 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Piracetam up to 1,200 mg/day
Number of subjects: 16
Study: 10691219

Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB) with bupivacaine followed by neurolysis during fluoroscopic control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Repeated retrocrural neurolysis
Number of subjects: 50
Study: 9347368

Group type: EXPERIMENTAL
Intervention: Dopexamine (up to 2.0 micrograms/kg per min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dopamine (up to 6.0 micrograms/kg per min)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 70
Study: 7910083

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group A)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Open cholecystectomy (group B)
Number of subjects: 101
Study: 3723213

Group type: EXPERIMENTAL
Intervention: Vapor from carbonless forms
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bond paper (control)
Number of subjects: 30
Study: 30614136

Group type: EXPERIMENTAL
Intervention: CBT emphasizing exercise during behavioural activation (CBT‐E)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CBT emphasizing pleasurable low‐energy activities (CBT‐C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nondepressed age- and sex-matched controls
Number of subjects: 98
Study: 28816894

Group type: EXPERIMENTAL
Intervention: ORIF (open reduction and internal fixation)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 301
Study: 25803435

Group type: COMPARATOR
Intervention: Lightwand only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lightwand under direct laryngoscopy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lightwand with WEI JET under direct laryngoscopy
Number of subjects: 90
Study: 22893313

Group type: EXPERIMENTAL
Intervention: BU-rATG (n = 69)
Number of subjects: 139

Group type: COMPARATOR
Intervention: TBI (n = 70)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study: 21191122

Group type: EXPERIMENTAL
Intervention: Positive frame
Number of subjects: 298

Group type: COMPARATOR
Intervention: Negative frame
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Combined frame
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Percentage format
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Frequency format
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Highly numerate participants
Number of subjects: 298
Study: 22029560

Group type: EXPERIMENTAL
Intervention: Step dance sessions of 50 min per day, 3 days per week for 10 weeks with 60‐80% of heart rate reserves
Number of subjects: 138

Group type: COMPARATOR
Intervention: Lecture control group (no organized or structured exercise)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Step dance sessions
Number of subjects: 138
Study: 17101405

Group type: EXPERIMENTAL
Intervention: SPIO-enhanced T(2)-weighted MRI
Number of subjects: 32

Group type: COMPARATOR
Intervention: unenhanced T(2)-weighted MRI
Number of subjects: 32
Study: 15003745

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) for 2 months, weekly sessions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Home visit only
Number of subjects: 31
Study: 11674983

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 70
Study: 9566819

Group type: EXPERIMENTAL
Intervention: a‐interferon (10 million units then 5 million units three times weekly for 6 to 12 months)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: a‐interferon
Number of subjects: 410

Group type: COMPARATOR
Intervention: relapsers/non-responders
Number of subjects: 410
Study: 7771262

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other sulphonylureas or placebo
Number of subjects: 0
Study: 3338249

Group type: EXPERIMENTAL
Intervention: Large protein load (1.35 g/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Moderate protein load (1.08 g/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mild protein load (0.55 g/kg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (carbohydrate meal)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Large and moderate protein loads
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All protein loads
Number of subjects: 37
Study: 29600568

Group type: EXPERIMENTAL
Intervention: Long-term rehabilitation programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biopedagogies
Number of subjects: 0
Study: 28558062

Group type: COMPARATOR
Intervention: AmBisome monotherapy (5 mg/kg single dose)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: AmBisome + paromomycin (5 mg/kg single dose + 10 days of paromomycin at 15 mg/kg/day)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: AmBisome + miltefosine (5 mg/kg single dose + 7 subsequent days of miltefosine at 2.5 mg/kg/day)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Paromomycin + miltefosine (10 days of paromomycin at 15 mg/kg/day + miltefosine at 2.5 mg/kg/day)
Number of subjects: 601
Study: 26201546

Group type: EXPERIMENTAL
Intervention: Comprehensive technology-assisted training and supervision program
Number of subjects: 434

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 434
Study: 23523641

Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 385

Group type: COMPARATOR
Intervention: Non-TB (control group)
Number of subjects: 385
Study: 21751905

Group type: EXPERIMENTAL
Intervention: Albuterol inhaler
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 39

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 39
Study: 18712479

Group type: EXPERIMENTAL
Intervention: NaP-45/45
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: NaP-45/30
Number of subjects: 121

Group type: COMPARATOR
Intervention: PEG-2L
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: NaP-45/45, NaP-45/30, PEG-2L
Number of subjects: 121
Study: 16820579

Group type: EXPERIMENTAL
Intervention: GIK (40% dextrose, K+ 100 mmol.L(‐1), insulin 70 u.L(‐1); 0.75 mL.kg(‐1).h(‐1) for 6 hours after aortic cross-clamp removal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 48
Study: 15229965

Group type: EXPERIMENTAL
Intervention: human recombinant growth hormone (GH) for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo for 6 months
Number of subjects: 25
Study: 11164716

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 547
Study: 9232301

Group type: EXPERIMENTAL
Intervention: Sublingual midazolam 7.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral midazolam 7.5 mg
Number of subjects: 100
Study: 7960816

Group type: EXPERIMENTAL
Intervention: Postnatal care following premature birth
Number of subjects: 0
Study: 14591268

Group type: EXPERIMENTAL
Intervention: Formal memory remediation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment focusing on psychosocial issues
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subdivided groups based on severity of neuropsychological functioning
Number of subjects: 20
Study: 29493708

Group type: EXPERIMENTAL
Intervention: Image‐guided Robotic Assisted Surgical simulator (IRAS) with robotic guidance
Number of subjects: 42
Study: 28057452

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 49
Study: 26970464

Group type: EXPERIMENTAL
Intervention: BCG 0.1mg
Number of subjects: 281161

Group type: EXPERIMENTAL
Intervention: BCG 0.01mg
Number of subjects: 281161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281161
Study: 22843552

Group type: EXPERIMENTAL
Intervention: Indicator-guided puncture technique (PCK)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard surgical technique (ST)
Number of subjects: 30
Study: 16724889

Group type: EXPERIMENTAL
Intervention: 8-week culturally targeted nutrition and physical activity intervention
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 366
Study: 14642938

Group type: EXPERIMENTAL
Intervention: STAN monitoring
Number of subjects: 173
Study: 10888376

Group type: EXPERIMENTAL
Intervention: Anatomical approach (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional approach (Group P)
Number of subjects: 43
Study: 8545150

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (Imitrex, Glaxo)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1975196

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg (B10)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg (B20)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg (B40)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 80 mg (B80)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol 40 mg (P40)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol (all doses)
Number of subjects: 6
Study: 6791563

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 110

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 110
Study: 30056141

Group type: EXPERIMENTAL
Intervention: Active tDCS plus computerized cognitive training (CCT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS plus CCT
Number of subjects: 22
Study: 28610572

Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline infusion with pulmonary recruitment maneuver (pressure of 40 cm H2O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with carbon dioxide removal through gentle abdominal pressure and passive exsufflation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline infusion with pulmonary recruitment maneuver
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with carbon dioxide removal
Number of subjects: 0
Study: 26386749

Group type: EXPERIMENTAL
Intervention: Project Stride (equine-assisted activities and cognitive-behavioral strategies)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 12
Study: 24074405

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multi-incision laparoscopic cholecystectomy (MILC)
Number of subjects: 100
Study: 20619577

Group type: EXPERIMENTAL
Intervention: Diabetes-specific web-based 'Coping with Depression' (CWD) course; 8-lesson intervention with minimal guidance by coaches.
Number of subjects: 255
Study: 17998306

Group type: EXPERIMENTAL
Intervention: Antidepressant pharmacotherapy in comparator trials
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antidepressant pharmacotherapy in placebo-controlled trials
Number of subjects: 16
Study: 15689713

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered intramuscularly at 9 x 10 IU daily for the first 4 weeks and then three times per week for the next 20 weeks.
Number of subjects: 98
Study: 12804846

Group type: EXPERIMENTAL
Intervention: 20 micrograms of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 micrograms of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB)
Number of subjects: 0
Study: 10098223

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9010119

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (specific drugs not mentioned)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 209

Group type: COMPARATOR
Intervention: Excluded patients with suicidal thoughts or intent
Number of subjects: 209
Study: 1911582

Group type: EXPERIMENTAL
Intervention: Supportive companionship during labour
Number of subjects: 149
Study: 7126388

Group type: EXPERIMENTAL
Intervention: Propranolol (2 to 16 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol (10 to 80 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study: 31493477

Group type: EXPERIMENTAL
Intervention: Forced Air Warming (FAW)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Resistive Fabric Warming (RFW)
Number of subjects: 515
Study: 29237746

Group type: EXPERIMENTAL
Intervention: Telemonitoring (756 patients)
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Usual care (765 patients)
Number of subjects: 1521
Study: 23581606

Group type: EXPERIMENTAL
Intervention: Liquid silicone gel (LSG) applied to hypertrophic scars (HS group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Silicone gel alone (control for HS group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Liquid silicone gel (LSG) applied to minor keloids (KS group)
Number of subjects: 30
Study: 25065086

Group type: COMPARATOR
Intervention: Midazolam/meperidine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 48
Study: 22931975

Group type: EXPERIMENTAL
Intervention: Sevoflurane at various concentrations (0.2% to 3.4%) combined with remifentanil (1, 3, 6, and 10 ng/ml)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Remifentanil alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sevoflurane concentrations (1.04 ± 0.19)% to (1.81 ± 0.21)%
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sevoflurane and remifentanil combination
Number of subjects: 65
Study: 19778675

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with apical lead position
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with midventricular lead position
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with basal lead position
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 80
Study: 17519258

Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic field therapy (PMFT) for 30 min (1.25 Hz, 3 ms width, 600 Gauss)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham pulsed magnetic field therapy (deactivated device) for 30 min
Number of subjects: 10
Study: 15239219

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g once daily
Number of subjects: 902

Group type: COMPARATOR
Intervention: Standard therapy (second‐generation cephalosporin, broad‐spectrum penicillin or a combination of aminopenicillin and beta‐lactamase inhibitor)
Number of subjects: 902
Study: 11297956

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 20709
Study: 9875190

Group type: COMPARATOR
Intervention: Topical class 3 corticosteroids
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topical class 4 corticosteroids
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral methoxsalen plus sunlight
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral psoralen plus sunlight
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral trioxsalen plus sunlight
Number of subjects: 63

Group type: COMPARATOR
Intervention: Narrowband UV‐B
Number of subjects: 63

Group type: COMPARATOR
Intervention: Broadband UV‐B
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral methoxsalen plus UV‐A therapy
Number of subjects: 63
Study: 7662616

Group type: EXPERIMENTAL
Intervention: Gelatin capsules coated with 20% w/v sodium alginate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncoated gelatin capsules
Number of subjects: 0
Study: 2748113

Group type: EXPERIMENTAL
Intervention: Epinephrine treatment with Ocufen (flurbiprofen)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Epinephrine treatment with Indocid (indomethacin)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Epinephrine treatment alone
Number of subjects: 216

Group type: COMPARATOR
Intervention: Ocufen (flurbiprofen) without epinephrine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Indocid (indomethacin) without epinephrine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo without epinephrine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Ocufen + epinephrine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Indocin without epinephrine
Number of subjects: 216
Study: 201786

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin 2000 mg per day
Number of subjects: 0
Study: 31297659

Group type: EXPERIMENTAL
Intervention: Direct technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Semi-direct technique
Number of subjects: 30
Study: 30883766

Group type: EXPERIMENTAL
Intervention: Circulating VASPIN concentrations measured by ELISA
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Genetic variants in VASPIN
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis using VASPIN SNP
Number of subjects: 823
Study: 28273285

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 2198

Group type: COMPARATOR
Intervention: Heparin plus optional GPIs (control group)
Number of subjects: 2198
Study: 25932481

Group type: EXPERIMENTAL
Intervention: Short Form-36
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: CASP-19
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Questionnaire-18
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Health service usage
Number of subjects: 236
Study: 22898749

Group type: EXPERIMENTAL
Intervention: Differential moments group (G1) with a nickel titanium (NiTi) intrusion arch and a 150g NiTi closing coil spring for canine retraction.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Temporary anchorage devices (TAD) group (G2) with one miniscrew placed between maxillary second premolars and first molars and a 150g NiTi closing coil spring.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups (G1 and G2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TAD group (G2)
Number of subjects: 28
Study: 21737486

Group type: EXPERIMENTAL
Intervention: FDTV 180 mg + T 2 mg, once a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: T 2 mg once a day
Number of subjects: 40
Study: 18688627

Group type: EXPERIMENTAL
Intervention: Pectoralis major myocutaneous flap with adjuvant radiotherapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 7
Study: 16520326

Group type: EXPERIMENTAL
Intervention: 900 MHz GSM mobile phone signal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: non‐pulsing carrier wave signal
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham condition with no signal present
Number of subjects: 120